Several target genes of top hits are regarded as classical melanoma tumor suppressors, such as PTEN and NF1. These enhancers are associated with highly recurrent loss-of-function events in melanoma patients, which implies that tumors may acquire survival advantages by disrupting the genomic sequence of these enhancers, thus decreasing the expression level of their tumor suppressor targets. This evidence concerns the gene NF1 and melanoma.